Elagolix GnRH Antagonist for Endometriosis Pain: Mechanism, Dosing, Bone and Mood Safety

　　1.Profile and Mechanism

　　Elagolix competitively binds pituitary GnRH receptors,suppressing endogenous GnRH signaling in a dose-dependent manner,reducing LH and FSH and subsequently ovarian estradiol and progesterone.Lower estrogen decreases endometriotic lesion activity,inflammation,and pain.As a non-peptide oral antagonist,it avoids the initial flare seen with GnRH agonists and acts faster;lower doses give partial estrogen suppression,higher doses nearer complete suppression.

　　2.Versus Analgesics and Oncology Targeted Therapy

　　Versus analgesics:NSAIDs or acetaminophen act mainly on pain/inflammation pathways;elagolix modifies the hypothalamic–pituitary–ovarian axis and is disease-directed endocrine therapy,not symptomatic-only analgesia.

　　Versus tumor targeting:oncology targeted drugs usually address driver mutations or proteins such as EGFR,ALK,or HER2;elagolix targets the GnRH receptor to regulate reproductive hormones and is not antitumor,not selected by tumor gene mutations.

　　3.Indications and Case Selection

　　Use in diagnosed or surgically confirmed endometriosis with moderate-to-severe pain:

　　dysmenorrhea or chronic non-menstrual pelvic pain affecting function;

　　prominent dyspareunia,where 200mg twice daily may be considered for a limited period;

　　preference for oral therapy and avoidance of GnRH agonist injection flare;

　　after weighing NSAIDs,combined hormonal contraceptives,progestins,dienogest,and surgical options by pain pattern,bone risk,fertility plan,liver function,and mood history.

　　It reduces pain and lesion activity but does not cure endometriosis;pain may return after stopping.

　　4.Dosing and Duration

　　Normal/mild hepatic impairment:150mg once daily,approximately same time each day with or without food,for dysmenorrhea and non-menstrual pelvic pain up to about 24 months;200mg twice daily about 12 hours apart for more severe pain or dyspareunia up to about 6 months.

　　Moderate hepatic impairment,Child-Pugh B:150mg once daily only,up to about 6 months;200mg twice daily not recommended.

　　Severe hepatic impairment:do not start.

　　Exclude pregnancy before starting or begin within 7 days of menses;if a dose is missed,take it the same day and never double—maximum one 150mg tablet per day or two 200mg tablets per day.

　　Use the lowest effective dose based on pain relief,not maximal suppression by default.

　　5.Monitoring and Stop Signals

　　Bone:dose-and duration-dependent BMD loss,possibly incomplete recovery.Assess fracture history,low body weight,steroid use,smoking,vitamin D deficiency;DXA for high-risk patients;calcium and vitamin D as needed.

　　Menstruation and pregnancy:reduced or absent bleeding can delay pregnancy recognition.Use non-hormonal contraception during treatment and for the period stated in the local label;test if pregnancy is suspected and discontinue if confirmed.

　　Mood:depression,anxiety,insomnia,and rare suicidal ideation occur;history of mood disorder requires closer follow-up,and new/worsening hopelessness or self-harm thoughts warrants immediate evaluation and possible discontinuation.

　　Liver:dose-related ALT elevations;jaundice,dark urine,right-upper-quadrant pain,or marked transaminase rise needs hepatology review.

　　Estrogen-deficiency effects:hot flushes,night sweats,vaginal dryness,arthralgia,lowered libido—more frequent with 200mg twice daily.

　　Lipids:monitor cholesterol and triglycerides with long-term or high-risk use.

　　Common adverse events:hot flushes/night sweats,headache,nausea,insomnia,amenorrhea,anxiety,arthralgia,depression-related reactions,mood changes.

　　Interactions:CYP3A inducers such as rifampin lower exposure;strong OATP1B1 inhibitors such as cyclosporine or gemfibrozil markedly raise exposure and are contraindicated/avoided;monitor digoxin,some statins,midazolam;estrogen-containing contraceptives may reduce elagolix efficacy,progestin-only contraceptive data are limited.

　　6.Cautions and Contraindications

　　Avoid in pregnancy,known osteoporosis,severe hepatic impairment,hypersensitivity,or concomitant strong OATP1B1 inhibitors that substantially increase elagolix levels.Safety in under-18 is not established;in lactation weigh risks and benefits.Uncontrolled depression,active hepatitis,severe low bone mass,or recent fragility fracture should be assessed by gynecology-endocrinology before use.